Regeneron Pharmaceuticals, Inc Patent Portfolio Statistics

Regeneron Pharmaceuticals, Inc.

Profile Summary

This article summarizes the perfomance of the assignee in the recent years. The overall statistics for this portfolio help to analyze the areas where the assignee is performing well. The filing trend, perfomance across the tech centers and the perfomance of the recent applications has been mentioned below. All the stats are calculated based on the perfomance in USPTO.

How does the overall patent portfolio of Regeneron Pharmaceuticals, Inc. look like?

Total Applications: 1,362
Granted Patents: 747
Grant Index 76.15 %
Abandoned/Rejected Applications: 234 (23.85%)
In-Process Applications: 370
Average Grant Time: 2.54 Years
Average Office Actions: 1.71

Which Technology Area Regeneron Pharmaceuticals, Inc. is filing most patents in? (Last 10 years)

Art Unit Definition Total Applications
1647 Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology 215
1632 Molecular Biology, Bioinformatics, Nucleic Acids, Recombinant DNA and RNA, Gene Regulation, Nucleic Acid Amplification, Animals and Plants, Combinatorial/ Computational Chemistry 205
1646 Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology 148
1633 Molecular Biology, Bioinformatics, Nucleic Acids, Recombinant DNA and RNA, Gene Regulation, Nucleic Acid Amplification, Animals and Plants, Combinatorial/ Computational Chemistry 143
Opap Parked GAU 118

How many patents are Regeneron Pharmaceuticals, Inc. filing every year?

Year Total Applications
2022 0*
2021 61*
2020 145
2019 155
2018 161

*The drop in the number of applications filed in last two years compared to previous years is because applications can take up to 18 months to get published

Recently filed patent applications of Regeneron Pharmaceuticals, Inc. in USPTO?

Publication number: US20220025029A1
Application number: 17/500,418

Abstract:
The present invention provides antibodies that bind to the cat allergen, Fel d1, compositions comprising the antibodies, nucleic acids encoding the antibodies and methods of use of the antibodies. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Fel d1. The antibodies of the invention are useful for binding to the Fel d1 allergen in vivo, thus preventing binding of the Fel d1 allergen to pre-formed IgE on the surface of mast cells or basophils. In doing so, the antibodies act to prevent the release of histamine and other inflammatory mediators from mast cells and/or basophils, thus ameliorating the untoward response to the cat allergen in sensitized individuals. The antibodies of the invention may also be useful for diagnostic purposes to determine if a patient is allergic to the Fel d1 cat allergen.

Publication date: 2022-01-27
Applicant: Regeneron Pharmaceuticals, Inc.
Inventors: Jamie Orengo


Publication number: US20220024973A1
Application number: 17/496,263

Abstract:
A bispecific antibody format providing ease of isolation is provided, comprising immunoglobulin heavy chain variable domains that are differentially modified in the CH3 domain, wherein the differential modifications are non-immunogenic or substantially non-immunogenic with respect to the CH3 modifications, and at least one of the modifications results in a differential affinity for the bispecific antibody for an affinity reagent such as Protein A, and the bispecific antibody is isolable from a disrupted cell, from medium, or from a mixture of antibodies based on its affinity for Protein A.

Publication date: 2022-01-27
Applicant: Regeneron Pharmaceuticals, Inc.
Inventors: Davis Samuel


Publication number: US20220023529A1
Application number: 17/495,407

Abstract:
According to one aspect of the disclosure, packaging for a sterile syringe having a nominal size of less than 1 mL may include a flexible tray having a cavity for containing the syringe. The cavity may include an opening, one or more sidewalls, and a base. A lip may surround the opening, may extend radially outward from the cavity, and may define a periphery of the tray. A removable cover may have a periphery that is adhered to the lip, and the removable cover may be permeable to a gaseous sterilant, including one or more of vaporized hydrogen peroxide or ethylene oxide. A projection may be associated with the base of the cavity and may extend away from the base of the cavity in a direction opposite to the opening of the cavity.

Publication date: 2022-01-27
Applicant: Regeneron Pharmaceuticals, Inc.
Inventors: Bradford Victor


How are Regeneron Pharmaceuticals, Inc.’s applications performing in USPTO?

Application Number Title Status Art Unit Examiner
17/500,418 Human Antibodies To Fel D1 And Methods Of Use Thereof OPAP Central, Docket
17/496,263 Readily Isolated Bispecific Antibodies With Native Immunoglobulin Format OPAP Central, Docket
17/495,407 Medical Device Packaging And Related Methods OPAP Central, Docket
17/489,495 Anti-Vegf Protein Compositions And Methods For Producing The Same 1654 Russel, Jeffrey E
17/483,588 Multispecific Antigen-Binding Molecules And Uses Thereof OPAP Central, Docket